NZ237176A - Insulin cobalt iii complex compositions - Google Patents
Insulin cobalt iii complex compositionsInfo
- Publication number
- NZ237176A NZ237176A NZ237176A NZ23717691A NZ237176A NZ 237176 A NZ237176 A NZ 237176A NZ 237176 A NZ237176 A NZ 237176A NZ 23717691 A NZ23717691 A NZ 23717691A NZ 237176 A NZ237176 A NZ 237176A
- Authority
- NZ
- New Zealand
- Prior art keywords
- insulin
- iii
- ins
- pharmaceutical composition
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Chairs For Special Purposes, Such As Reclining Chairs (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK045590A DK45590D0 (enExample) | 1990-02-21 | 1990-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ237176A true NZ237176A (en) | 1991-12-23 |
Family
ID=8093754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ237176A NZ237176A (en) | 1990-02-21 | 1991-02-20 | Insulin cobalt iii complex compositions |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0516704B1 (enExample) |
| JP (1) | JPH05503940A (enExample) |
| AU (1) | AU641991B2 (enExample) |
| CA (1) | CA2075982A1 (enExample) |
| DE (1) | DE69100626D1 (enExample) |
| DK (1) | DK45590D0 (enExample) |
| HU (1) | HUT63858A (enExample) |
| IE (1) | IE910579A1 (enExample) |
| NZ (1) | NZ237176A (enExample) |
| PT (1) | PT96841A (enExample) |
| WO (1) | WO1991012817A1 (enExample) |
| ZA (1) | ZA911279B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9316895D0 (en) * | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
| US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| BR9407508A (pt) * | 1993-09-17 | 1997-01-07 | Novo Nordisk As | Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| US6451762B1 (en) | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| CA2531988C (en) | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| ES2402592T3 (es) | 2003-08-05 | 2013-05-07 | Novo Nordisk A/S | Nuevos derivados de insulina |
| ES2438145T3 (es) | 2005-02-02 | 2014-01-16 | Novo Nordisk A/S | Nuevos derivados de insulina |
| JP4808785B2 (ja) | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー／エス | インスリン組成物および組成物の製造方法 |
| JP5550338B2 (ja) | 2006-07-31 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | ペグ化持続型インスリン |
| US9018161B2 (en) | 2006-09-22 | 2015-04-28 | Novo Nordisk A/S | Protease resistant insulin analogues |
| US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| ES2618073T3 (es) | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| EP2352513B1 (en) | 2008-10-30 | 2016-09-14 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| HRP20191793T1 (hr) | 2010-10-27 | 2019-12-27 | Novo Nordisk A/S | Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja |
| EP2836508B1 (en) | 2012-04-11 | 2016-06-29 | Novo Nordisk A/S | Insulin formulations |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| JP6499184B2 (ja) | 2013-10-07 | 2019-04-10 | ノヴォ ノルディスク アー／エス | インスリン類似体の新規な誘導体 |
| EP3821905B1 (en) | 2016-12-16 | 2022-10-12 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| WO2021009027A1 (en) | 2019-07-12 | 2021-01-21 | Novo Nordisk A/S | High concentration insulin formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE971500C (de) * | 1950-11-22 | 1959-02-05 | Organon Nv | Verfahren zur Herstellung von Insulin-Suspensionen mit verlaengerter Wirkung |
| DE1107374B (de) * | 1958-01-31 | 1961-05-25 | Organon Nv | Verfahren zur Herstellung eines Insulin-Praeparates |
-
1990
- 1990-02-21 DK DK045590A patent/DK45590D0/da not_active Application Discontinuation
-
1991
- 1991-02-20 IE IE057991A patent/IE910579A1/en unknown
- 1991-02-20 NZ NZ237176A patent/NZ237176A/en unknown
- 1991-02-21 CA CA002075982A patent/CA2075982A1/en not_active Abandoned
- 1991-02-21 AU AU73378/91A patent/AU641991B2/en not_active Expired - Fee Related
- 1991-02-21 HU HU922721Q patent/HUT63858A/hu unknown
- 1991-02-21 JP JP3504590A patent/JPH05503940A/ja active Pending
- 1991-02-21 EP EP91904980A patent/EP0516704B1/en not_active Expired - Lifetime
- 1991-02-21 ZA ZA911279A patent/ZA911279B/xx unknown
- 1991-02-21 DE DE91904980T patent/DE69100626D1/de not_active Expired - Lifetime
- 1991-02-21 PT PT96841A patent/PT96841A/pt not_active Application Discontinuation
- 1991-02-21 WO PCT/DK1991/000052 patent/WO1991012817A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| HU9202721D0 (en) | 1992-12-28 |
| DE69100626D1 (de) | 1993-12-16 |
| IE910579A1 (en) | 1991-08-28 |
| DK45590D0 (enExample) | 1990-02-21 |
| HUT63858A (en) | 1993-10-28 |
| JPH05503940A (ja) | 1993-06-24 |
| AU7337891A (en) | 1991-09-18 |
| EP0516704B1 (en) | 1993-11-10 |
| CA2075982A1 (en) | 1991-08-22 |
| PT96841A (pt) | 1991-11-29 |
| AU641991B2 (en) | 1993-10-07 |
| ZA911279B (en) | 1991-10-30 |
| EP0516704A1 (en) | 1992-12-09 |
| WO1991012817A1 (en) | 1991-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ237176A (en) | Insulin cobalt iii complex compositions | |
| US5266333A (en) | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone | |
| DE3885317T2 (de) | Makromolekulare Platin-Antitumorverbindungen. | |
| DE3880346T2 (de) | Insulinderivate. | |
| DE69425464T2 (de) | Polysaccharidderivat und wirkstoffträger | |
| DE69722397T2 (de) | Insulin-derivate und ihre verwendung | |
| KR890004687B1 (ko) | 생물학적 활성 서방출성 조성물 | |
| DE69631824T2 (de) | Biologisch abbaubare nanopartikel mit kontrollierter freigabe von insulin | |
| RU2432175C2 (ru) | N-концевое полисиалилирование | |
| DE69429169T2 (de) | Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält | |
| Zhang et al. | Polymer–covalent organic frameworks composites for glucose and PH dual‐responsive insulin delivery in mice | |
| EP3554534B1 (en) | Insulin containing pharmaceutical compositions | |
| EP0646379A1 (en) | Insulin formulation | |
| WO1995005848A1 (en) | Protracted glp-1 | |
| JPH10511365A (ja) | 遅延性ｇｌｐ−１組成物 | |
| CN109069590A (zh) | 包含聚山梨酯80的胰岛素制剂 | |
| EP0119650A2 (en) | Galactosyl-insulin conjugates useful in treating diabetics | |
| CA1335924C (en) | Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals, and the use thereof for the treatment of diabetes mellitus | |
| HUT59942A (en) | Process for producing glycozylized inzulines | |
| ZA200600846B (en) | Novel insulin derivatives | |
| Enriquez et al. | Conjugation of adenine arabinoside 5'-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity | |
| EP4591875A1 (en) | Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof | |
| CA2463769A1 (en) | Composition and method for treating diabetes | |
| TW201934137A (zh) | 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法 | |
| DE2646223C2 (enExample) |